Stock 603567 HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Heilongjiang ZBD Pharmaceutical Co., Ltd.

Equities

603567

CNE100002219

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
10.53 CNY -0.38% Intraday chart for Heilongjiang ZBD Pharmaceutical Co., Ltd. -7.14% -13.40%
05-27 ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets MT
05-07 China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets
China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
HeiLongJiang ZBD Pharma Registers Osteoarthritis Drug
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies
Heilongjiang ZBD Gets Approval for Traditional Medicine Product
Heilongjiang ZBD’s Anti-Pulmonary Fibrosis Drug Gets U.S. Patent
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) completed the acquisition of 5% stake in Heilongjiang ZBD Pharmaceutical Co., Ltd. from Hulin Longpeng Investment Center.
Heilongjiang ZBD Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.
Heilongjiang ZBD Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603567 Stock
  4. News Heilongjiang ZBD Pharmaceutical Co., Ltd.
  5. Other languages